TRPV2 and esophageal squamous cell carcinoma: The inhibition of TRPV2 by tranilast; inhibition of ANO1 by T16Ainh-A01, digallic acid, and tannic acids; and the inhibition of voltage-gated sodium channels by valproic acid were reported as potential targeted therapeutic agents in esophageal squamous cell carcinoma (Shiozaki et al., 2018; Capatina et al., 2022; Bill et al., 2014; Wheler et al., 2014).